Maze Therapeutics, a clinical-stage biopharmaceutical company, announced the dosing of the first patient in its Phase 2 clinical trial, the HORIZON Study, which is investigating MZE829, an oral APOL1 ...
SOUTH SAN FRANCISCO – Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 ...
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results